Analgesics in New Zealand is expected to maintain slow and stable retail current value growth in the forecast period. Within systemic analgesics, although rising from a low base, diclofenac is set to see the strongest rate of retail current value growth, while ibuprofen will continue to account for the highest sales.
While the government has relaxed restrictions on the sale and supply of OTC products containing pseudoephedrine in 2024, the impact of this change remains uncertain. Internationally, leading analgesics brands such as Panadol offer variants containing pseudoephedrine; however, against a backdrop of heightened levels of retail crime over the review period, seeing vape stores, convenience stores, and jewellery stores targeted by ram raids, pharmacies have expressed a reluctance to stock and sell products containing pseudoephedrine, given the association these products have with organised crime, as it is used as an ingredient in the manufacture of methamphetamine.
Product performance and efficacy are major attributes affecting decision-making within analgesics, as consumers want to purchase products which they know will treat their need. Thus, the brand equity and trust enjoyed by popular brands such as Panadol (Haleon New Zealand ULC) and Nurofen (Reckitt Benckiser New Zealand Ltd) will ensure these brands continue to lead the category over the forecast period.
Delivery:
Files are delivered directly into your account soon after payment is received and any tax is certification is verified (where applicable).
This report comes in PDF with additional info in Excel included.
Understand the latest market trends and future growth opportunities for the Analgesics industry in New Zealand with research from Euromonitor International's team of in-country analysts – experts by industry and geographic specialisation.
Key trends are clearly and succinctly summarised alongside the most current research data available. Understand and assess competitive threats and plan corporate strategy with our qualitative analysis, insight and confident growth projections.
If you're in the Analgesics industry in New Zealand, our research will help you to make informed, intelligent decisions; to recognise and profit from opportunity, or to offer resilience amidst market uncertainty.
Analgesics
Analgesics cover systemic and topical pain relievers. Products which include a pain-relief ingredient in addition to another core function are excluded (e.g. a sore throat remedy which includes paracetamol is excluded from the analgesics and instead is included in pharyngeal remedies).
See All of Our DefinitionsThis report originates from Passport, our Analgesics research and analysis database.
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extraction Free!